Form 4 for OPRX OptimizeRx Corp
Accepted 2023-01-31 00:00:00 ET · period of report 2023-01-07 · accession 0001628280-23-001817 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-31 | 2023-01-07 | OPRX | FEBBO WILLIAM J | CEO, Dir | M - OptEx | — | +9,628 | 471.4K | +2% | — |
| D | 2023-01-31 | 2023-01-07 | OPRX | FEBBO WILLIAM J | CEO, Dir | M - OptEx | $0.00 | -9,628 | 9,628 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-07 | M | A | 9,628 | — | 471,400 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. |
| 2 | Derivative | Restricted Stock Units | 2023-01-07 | M | D | 9,628 | $0.00 | 9,628 | D | — · — to — | 9,628 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F2) On January 7, 2021, the reporting person was granted 28,883 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |